BEXIMCO PHARMACEUTICALS

LTD ~ COMPANY BEFORE &

AFTER FIVE (05) YEARS
STRATEGY.

Sustainable development goals
One of the main outcomes of the Rio+20 Conference was the agreement by member States to launch a
process to develop a set of Sustainable Development Goals SDGs!" which will build upon the #illennium
Development Goals and converge with the post 20$% development agenda clic& here for information on
different wor& streams!' (t was decided establish an )inclusive and transparent intergovernmental process
1
open to all stakeholders, with a view to developing global sustainable development goals to be agreed by
the General Assembly)'
(n the Rio+20 outcome document" member States agreed that sustainable development goals SDGs! must*
$' +e based on ,genda 2$ and the -ohannesburg .lan of (mplementation'
2' /ully respect all the Rio .rinciples'
0' +e consistent with international law'
1' +uild upon commitments already made'
%' Contribute to the full implementation of the outcomes of all ma2or summits in the economic" social
and environmental fields'
3' /ocus on priority areas for the achievement of sustainable development" being guided by the
outcome document'
4' ,ddress and incorporate in a balanced way all three dimensions of sustainable development and
their interlin&ages'
5' +e coherent with and integrated into the 6nited 7ations development agenda beyond 20$%'
8' 7ot divert focus or effort from the achievement of the #illennium Development Goals'
$0' (nclude active involvement of all relevant sta&eholders" as appropriate" in the process'
(t was further agreed that SDGs must be*
,ction9oriented
Concise
:asy to communicate
;imited in number
,spirational
Global in nature
6niversally applicable to all countries while ta&ing into account different national realities"
capacities and levels of development and respecting national policies and priorities'
<he outcome document further specifies that the development of SDGs should*
+e useful for pursuing focused and coherent action on sustainable development
Contribute to the achievement of sustainable development
Serve as a driver for implementation and mainstreaming of sustainable development in the 67
system as a whole
,ddress and be focused on priority areas for the achievement of sustainable development
<he Rio+20 outcome document The Future We Want resolved to establish an inclusive and transparent
intergovernmental process on SDGs that is open to all sta&eholders with a view to developing global
sustainable development goals to be agreed by the 67G,' <he outcome document mandated the creation
of an inter9governmental Open =or&ing Group" that will submit a report to the 35th session of the General
,ssembly containing a proposal for sustainable development goals for consideration and appropriate action'
<he outcome document specifies that the process leading to the SDGs needs to be coordinated and
coherent with the processes considering the post 20$% development agenda and that initial input to the wor&
of the Open =or&ing Group will be provided by the 67SG in consultation with national governments'
2
C O M P A N Y B A C K G R O U N D A B O U T C O M P A N Y B A C K G R O U N D A B O U T
B E X I M C O P H A R M A C E U T I C A L S L T D . B E X I M C O P H A R M A C E U T I C A L S L T D .
Beximco Pharmaceuticals Ltd. is a leading edge pharmaceutical company and is a
member of the BEXIM! "roup# the largest pri$ate sector industrial conglomerate in
Bangladesh. %he strategic strengths of Beximco Pharma are its strong brand recognition#
highly s&illed 'or& force and di$ersified business mix. Beximco Pharma brands (
)eoceptin * +*anitidine,# )apa +Paracetamol,# -mdocal +-mlodipine,# )eofloxin
+iprofloxacin,# Bexitrol . +/almeterol Plus .luticasone,# Bextrum "old +Multi$itamin
and Multi Mineral, and -to$a +-tor$astatin, are among the most recogni0ed brands in
the Bangladesh Pharmaceutical industry.
Beximco Pharma started its operation in 1123# manufacturing products under the licenses
of Bayer -" of "ermany and 4p5ohn Inc. of 4/- and no' has gro'n to become nation6s
one of the leading pharmaceutical companies# supplying 178 of country6s total medicine
need. %oday Beximco Pharma manufactures and mar&ets its o'n 9branded generics6 for
almost all disease ran&ing from -I:/ to cancer# from infection to asthma# from
hypertension to diabetes# both nationally and internationally.
Beximco Pharma manufactures a range of dosage forms including tablets# capsules# dry
syrup# po'der# cream# ointment# suppositories# large $olume intra$enous fluids# metered
dose inhalers etc. in se$eral 'orld(class manufacturing plants# ensuring high ;uality
standards complying 'ith the <orld =ealth !rgani0ation +<=!, appro$ed current "ood
Manufacturing Practices +c"MP,.
%he recipient of three times 9gold6 national export trophy# Beximco Pharma is the largest
exporter of pharmaceuticals from Bangladesh# spreading its presence in many de$eloping
and de$eloped countries across the globe. Beximco Pharma is the only company in
Bangladesh to recei$e this highest national accolade for export# for record three times.
>
Beximco Pharma mar&ets its brands through professional sales and mar&eting teams in
-frican# -sian and European mar&ets. It also supplies its products to reno'ned hospitals
and institutions in many countries# including *affles =ospital and ? ? <omen @
hildren =ospital in /ingapore# ME:/ and ?enyatta )ational =ospital +?)=, in ?enya#
Ainnah =ospital# -gha ?han =ospital and /hau&at ?hanum Memorial =ospital in
Pa&istan. Beximco Pharma is also an enlisted supplier of <=! and4)IE..
-nother important business acti$ity of Beximco Pharma is the contract manufacturing for
ma5or international brands of leading multinational companies.
Beximco Pharma is acclaimed domestically and internationally for its outstanding
product ;uality# 'orld class manufacturing facilities# product de$elopment capabilities
and outstanding ser$ice.
Beximco Pharma has a strong mar&et focus and is anticipating continued future gro'th
by le$eraging business capabilities and de$eloping superior product brands and mar&ets.
In particular the company is $ery interested in de$eloping a strong export mar&et in 4/-
and Europe. %o meet the future demand Beximco Pharma has in$ested 4/B 73 million to
build a ne' state(of(the(art manufacturing plant# confirming to 4/.:- and 4? M=*-
standards. %his ne' plant 'ill also offer contract(manufacturing facility to leading
pharmaceutical companies# especially from Europe and 4/.
O R G A N I Z A T I O N A L O R G A N O G R A M O R G A N I Z A T I O N A L O R G A N O G R A M
C
B E F O R E F I V E Y E A R S S T R A T E G Y B E F O R E F I V E Y E A R S S T R A T E G Y
7
C!" V#$%"&
%rust and reliability to the products emerged as one of the core $alues of Beximco
Pharmaceuticals Limited. It maintains ;uality in manufacturing of products according to
the rules of the <=!. =iring a competent branch of people 'ho are best in their capacity
to ser$e the company best# strengthen the BPL function of operation .It also gi$e
emphasi0e on promoting ne' products through research and bringing cost efficiency in
business operations.
Beximco Pharma belie$es that it is in the business 'hich deals 'ith human health 'hich
ma&es it more responsible to &eep the highest standards of its products. %hrough its
products it tries to deli$er clear benefits to the patients.
"ood products# ho'e$er# are only one side of its expression of commitment. BPL
belie$es its responsibility lies e$en more in ensuring that the society gets benefited 'hile
it continues to gro'.
C!'!#(" S)*#$ R"&'+&*,*$*(*"&
orporate social responsibility is an integral part of BPLDs business strategy 'hich is
reflected in its mission statement. E$ery employee of the company &no's that the
company does not $ie' its success and achie$ements in financial terms only# but also in
terms of its deep relationship 'ith the society.
Each year# an increasing amount of contribution is ploughed bac& into social causes#
demonstrating Beximco Pharma6s commitment to the nation. More importantly the
company6s contribution extends beyond one(time donation to ongoing participation as
reflected in its partnership 'ith )"!s 'or&ing for -I:/ patients# in supporting sports#
and in raising disease a'areness among the people.
E
BPL donated medicines 'orth millions of ta&a to $ictims in national and international
calamities. :onation of medicines to $ictims of earth;ua&e in Pa&istan and $ictims of
tsunami in /ri Lan&a are 'orth mentioning.
%he company maintains a team of scientists 'ho 'or&s as pharmaceutical experts for
good go$ernance that gi$e direct benefit to the common people and shareholders.
Beximco Pharmaceuticals Limited carefully designed its facilities for reducing ha0ardous
impact on the en$ironment through operational excellence pro$iding a friendly
en$ironment for a healthy society for tomorro' being the main responsibility of BPL.
A F T E R F I V E Y E A R S S T R A T E G Y A F T E R F I V E Y E A R S S T R A T E G Y
F
M#+%-#)(%!*+. F#)*$*(*"&
Located at %ongi# near the capital city :ha&a# BPLDs manufacturing site is spread o$er an
area of 23 acres 'hich houses a number of self contained production units including oral
solids# metered dose inhalers# intra$enous fluids# li;uids# ointments# creams#
suppositories# ophthalmic drops# in5ectables# nebuli0er solutions etc. %he bul& drug unit
for producing paracetamol is also located 'ithin this site. ompanyDs penicillin -PI and
formulation units are situated at ?alia&oir# a fe' &ms from the main site.
%he plant and machinery throughout the site ha$e been designed by and procured mostly
from reno'ned European companies.
Beximco Pharma has its o'n utility infrastructure to ensure ade;uate generation and
distribution of purified 'ater at all times. %he installed capacity of po'er generation is 2
M<. %here is also li;uid nitrogen generation facility on site.
/%#$*(0 P$*)0
Beximco Pharmaceutical Limited6s mission is to achie$e business excellence through
;uality by understanding# accepting# meeting and exceeding customer expectations.
Beximco Pharmaceutical Limited +BPL, follo's International /tandards on Guality
Management /ystem to ensure consistent ;uality of products and ser$ices to achie$e
customer satisfaction. BPL also meets all national regulatory re;uirements relating to its
current businesses and ensures that current "ood Manufacturing Practices +c"MP, as
recommended by <orld =ealth !rgani0ation is follo'ed for its pharmaceutical
operations.
%he management of BPL commits itself to ;uality as the prime consideration in all its
business decisions. -ll employees of BPL must follo' documented procedures to ensure
compliance 'ith ;uality standards.
2
%he pool of human resources of the company 'ill be de$eloped to their full potential and
harnessed through regular training and their participation in see&ing continuous
impro$ement of 'or& methods.
E+1*!+2"+(#$ P$*)0
BPL is committed to maintain the harmonious balance of our eco(system and therefore
constantly see&s 'ays to manufacture and produce products in an eco(friendly manner so
that the balance of nature remains undisturbed and the en$ironment remains sustainable.
In pursuit of this goal# BPL 'ill comply fully 'ith all local and national en$ironmental
regulations.
onser$e natural resources li&e 'ater and energy for sustainable de$elopment# and adopt
en$ironmentally safe processes.
Ensure appropriate treatment of all effluents prior to discharge# to pre$ent pollution or
degradation of en$ironment.
Ensure appropriate communication and cooperate 'ith internal and external interested
parties on en$ironmental issues.
reate a'areness on en$ironmental issues among our employees and suppliers.
-dopt modern 'aste management technology.
P R E S E N T S T R A T E G I E S P R E S E N T S T R A T E G I E S
1
MARKET POLICY
D2"&(*) M#!3"(
Being a de$eloping country# the pharmaceutical mar&et and at the same time# the
pharmaceutical industry of Bangladesh is gro'ing. In this gro'ing mar&et# BPL has been
able to maintain its gro'th through its inno$ati$e mar&eting strategies.
In Bangladesh# BPL introduced the concept of ;uality management system by being the
first company to achie$e I/! 1331 certification that reflects its commitment to ;uality in
e$ery aspect of business.
BPL co$ers the health care community of 'hole Bangladesh based in both urban and
rural mar&ets# through its 12 strategically located depots.
I+("!+#(*+#$ M#!3"(
%o fuel the continuous gro'th of BPL# the company has started exploring international
mar&ets. %he ;uality of BPL products# strengthened by its I/! 1331 certification# has
brought immediate success in 4?# -merica# -ustralia# .rance# Bra0il# India# Pa&istan# /ri
Lan&a# Hemen# Myanmar and Iietnam.
R".%$#(!0 A''!1#$&
13
%he manufacturing facilities of Beximco Pharma ha$e been audited and appro$ed byJ
)ational =ealth /ur$eillance -gency +-)II/-,# Bra0il +M:I,
%herapeutic "oods -dministration +%"-,# -ustralia +!/:# M:I and /pray,
"ulf entral ommittee for :rug *egistration +for " member states,+!/: @
M:I,
Gualified by 4)IE. +M:I @ !/:,
Gualified by "lobal "laxo/mith?line +M:I,
Gualified by -sthma :rug .acility +-:.,# .rance +M:I,
Gualified by "lobal . =off Mann La *oche +!/:,
-ppro$als by 4? M=*- and 4/.:- are under process
!/:# !ral /olid :osageK M:I# Metered :ose Inhaler
R"&"#!)4 & D"1"$'2"+(
<ith strong re$erse engineering capability# 'e focus principally on de$eloping high
;uality generic formulations# matching the profile of inno$ator products. <e also focus
on simplifying manufacturing processes and impro$ing cost efficiency. !ur gro'ing
inno$ation is e$ident from successful launching of a number of ad$anced formulations
li&e multi(layer tablets# sustained release formulations# dispersible tablets# melt(in mouth
tablets# che'able $itamins etc. In proprietary research# 'e conducted collaborati$e
research 'ith iba /pecialty hemicals of /'it0erland. <ith !ur *@: team has
successfully de$eloped a range of .(free =.- M:Is. In addition# 'e are also
de$eloping a number of -PIs to ensure a$ailability of ra' materials across the range of
therapeutic classes. !ur capability to produce hi(tech# speciali0ed niche products as 'ell
as drug deli$ery systems has been our core strength to transform BPL into an inno$ation(
dri$en generic drug company.
11
C!'!#(" S)*#$ R"&'+&*,*$*(0
ommitment to our society is an integral part of the 'ay 'e are doing business. <e do
not 5udge our success in financial terms onlyK 'e $alue e$en more the deep relationship
'ith the society 'e li$e in. Each year# a substantial amount of our earning is ploughed
bac& into social causes# so that our society gets benefited 'hile 'e continue to gro'.
5. D+#(*+ - 2"6*)*+"&
<e donate and ma&e a$ailable a large ;uantity of medicines to the $ictims of natural
disasters# both national and international. Medicines for the $ictims of earth;ua&e in
Pa&istan# sunami in /ri Lan&a# and cyclone /I:* in Bangladesh are a fe' 'orth
mentioning.
7. P!1*6*+. T!"#(2"+( -! AIDS '#(*"+(& *+ B#+.$#6"&4
*esponding to the needs of thousands of -I:/ patients in the country# 'e are proud to be
associated 'ith the initiati$es to pro$ide treatment for these patients. /ince 2337#
Beximco Pharma has been supplying -*I drugs through :utch Bangla Ban&# a leading
local ban&# for treating the -I:/ patients in Bangladesh. %hese -*I drugs are distributed
through -shar -lo# Mu&to -&ash# and onfidential -pproach to -I:/ Pre$ention
+--P, ( )"!s 'or&ing for the =IIL-I:/ patients
8. O&"-$% ( -*.4( #.#*+&( A1*#+ #+6 S9*+" F$%
/ince its launch in March 233E# !seflu# BPLDs brand of oseltami$ir capsule# has been
donated to the go$t. of Bangladesh as 'ell as different reputed organi0ations including
I::*#B in response to the pandemic -$ian as 'ell as recent /'ine .lu. <e also
supplied !sefluM to the go$ernment of Myanmar as a part of our /* initiati$es
12
C+(!#)( M#+%-#)(%!*+. O''!(%+*(*"&
*ising cost of healthcare and medicines has become a global concern# and in order to
reduce cost across the $alue chain# pharmaceutical companies from de$eloped mar&ets
continue to loo& for suitable partners in de$eloping countries for shifting or outsourcing
their production. <ith decades of experience in generic drug manufacturing# 'orld class
capabilities as 'ell as significant cost ad$antages# Beximco Pharma can be an ideal
partner for you to meet your contract manufacturing needs. /ince its inception# Beximco
Pharma has established itself as a reliable partner for a number of 'orld6s leading
pharmaceutical companies. %he company has maintained a trac& record of sound
professionalism and its management has al'ays adhered to international standards
pro$iding a culture and 'or&ing en$ironment similar to that of a multinational company.
urrently the company has contract manufacturing agreement 'ith "laxo/mith?line
+"/?, for producing Metered :ose Inhaler product. %hese partnerships ha$e pro$ided
BPL much $aluable expertise and &no'(ho' to manufacture 'orld(class products.
%he company offers significant cost ad$antage as a manufacturer# as the a$erage 'age in
Bangladesh is probably the lo'est in the 'orld# and at least t'o to three times lo'er than
that in hina or India. Prospecti$e partners can benefit themsel$es 'ith competiti$e
ad$antages li&e a$ailability of highly s&illed manpo'er at a $ery lo' cost# lo' energy
cost# "o$t. policy support# in$estor friendly en$ironment etc.
1>
-fter &no'ing the 'hole strategic management techni;ues follo'ed by Beximco Pharma
it is clear that# no company can follo' one form or approach from the corporate le$el
strategy. /ituations $ary and so does the business strategies to meet the demand at a gi$en
point of time. =o'e$er# Beximco Pharma has also been that of a &ind 'here they
practiced different types of gro'th strategies# reached boom and at the same time
company follo'ed to the need for reco$ery stage 'here they ha$e gone through the
rene'al strategy. But more or less it can be said that Beximco Pharma preferred either
gro'th through mar&et de$elopments and if not so then stabilityK 'ith a consistent
approach to'ards consumer. <ell the sum up of the case study can be stated as that 'ith
all their superior strategies and techni;ues they ha$e continued to stay prosperous from
centuries and also hope to maintain that throughout.
1C